The phase 1b open-label, multicohort KEYNOTE-028 (NCT02054806) study corroborated the safety and anti-tumor efficacy of PD1 Ab (pembrolizumab) in ER+HER2- patients with PDL1+ tumors and prior endocrine therapies [12]. This evidence concerns the gene ESR1 and neoplasm.